Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07494773 · ClinicalTrials.gov registry record · Early Phase 1
Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection
A Early Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT07494773 is a Early Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 50 participants.
The verdict
NCT07494773, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Burn wound infections remain a major source of morbidity in patients with thermal injuries and contribute to delayed healing, graft loss, and prolonged hospitalization. The emergence of antimicrobial-resistant organisms further complicates management and highlights the need for non-antibiotic antimicrobial strategies. Photodynamic therapy (PDT) is an antimicrobial approach that combines a photosensitizing agent with visible light to generate reactive oxygen species capable of killing bacteria. This randomized clinical trial will evaluate the safety and preliminary efficacy of methylene blue-mediated photodynamic therapy for the treatment of burn wound bacterial contamination. Participants receiving standard burn care will be randomized to receive either methylene blue-photodynamic therapy with blue light illumination or light therapy alone during routine dressing changes. Treatments will occur during two consecutive dressing changes. The primary objective is to determine whether methylene blue photodynamic therapy reduces bacterial burden in burn wounds compared with light therapy alone. Secondary outcomes include safety, tolerability, and effects on wound healing.
Interventions
- DRUG Methylene Blue
- DEVICE Blue Light Illumination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07494773
The ClinicalTrials.gov registry entry for NCT07494773 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methylene Blue is the first listed.
NCT07494773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07494773 about?
NCT07494773 is a clinical study titled "Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection". Burn wound infections remain a major source of morbidity in patients with thermal injuries and contribute to delayed healing, graft loss, and prolonged hospitalization. The emergence of antimicrobial-resistant organisms further complicates management and highlights the need for non-antibiotic antimi...
What is the current status of trial NCT07494773?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2026-06. Estimated completion is 2028-05-31.
What interventions are being tested in trial NCT07494773?
The interventions under investigation include: Methylene Blue (DRUG), Blue Light Illumination (DEVICE).
Who is sponsoring clinical trial NCT07494773?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.